•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma: New Market Opportunity In The Emergency Setting